Slide 1: LD Micro Presentation
LD MICRO PRESENTATION 7 JUNE, 2023 S t e v e n Lyd e amo re - C EO NASDAQ: IMRN ASX: IMC 1
Slide 2: Safe Harbor Statement
Certain statements made in this presentation are forward - looking statements and are based on Immuron’s current expectations, estimates and projections. Words such as “anticipates,” “expects,” “ intends,” “ plans,” “ believes,” “ seeks,” “estimates,” “guidance” and s imilar expressions are intended
Slide 3: CEO Update & Corporate Snapshot
CEO UPDATE & CORPORATE SNAPSHOT Strengthening executive team – New Chief Commercial Officer Flavio Palumbo Flavio brings over 20 year’s experience with local and global (Asia, UK) commercial leadership roles with GSK and P&G Strong sales for Travelan® well above pre - pandemic levels, may result in
Slide 4: Executive Summary
EXECUTIVE SUMMARY Immuron Ltd (NASDAQ:IMRN) (ASX:IMC) is a globally integrated biopharmaceutical company focused on developing, and commercialising, oral immunotherapeutics for the treatment of gut mediated diseases • Two commercially available oral immunotherapeutic products – Travelan® and Protect
Slide 5: Technology Platform
TECHNOLOGY PLATFORM Bovine colostrum is the first milk of cows after calving. It is rich in immunoglobulins, lactoferrin, lysozyme, lactoperoxidase, growth factors and bioactive peptides. Colostrum has higher levels of protein, fat, vitamins, and minerals when compared to milk. This enables full dev
Slide 6: Status of Product Portfolio and Key Milestones
STATUS OF PRODUCT PORTFOLIO AND KEY MILESTONES US Department of Defense grant of US$4.45 million to examine a dosing regimen for Travelan® more suited for use by the military b • Market evaluation by Lumanity confirms the Traveler’s Diarrhea market opportunity for IMM - 124E (Travelan®) c • IMM - 12
Slide 7: Key Milestones Anticipated to Drive Value
KEY MILESTONES ANTICIPATED TO DRIVE VALUE • Topline results for IMM - 124E ETEC 2 clinical trial • Clinical Study Report • Completion of In - patient phase ETEC 2 CHIM 3 clinical trial • IRB Approval 4 • Initiated IMM - 124E ETEC 2 CHIM 3 clinical trial g • FDA IND 1 approved for single daily dose I
Slide 8: Immuron's Clinical Programs – Opportunity Assessment
IMMURON’S CLINICAL PROGRAMS – OPPORTUNITY ASSESSMENT › Immuron’s development of IMM - 124E (hyperimmune bovine colostrum) as a prescription medication has the potential to address this unmet need › Primary care physicians (PCP)s impressed with clinical efficacy endpoint targets demonstrating > 80% p
Slide 9: Distribution Capability
DISTRIBUTION CAPABILITY • The Australian retail network includes over 3,500 pharmacies • In the USA, the key B2B customer is Passport Health - the largest network of travel medicine clinics • Immuron’s own shopfront on amazon.com will be introduced in the USA during FY23 • Re - entry into retail pha
Slide 10: Addressable Market & Industry Overview
10 ADDRESSABLE MARKET & INDUSTRY OVERVIEW Industry tailwinds Travel picking up significantly following COVID lockdowns Frequent Symptom 30% - 70% of travelers experience traveler’s diarrhea*** ~$15b+ Immuron’s products are a subset of the global digestive health market, which a multi - billion - dol
Slide 11: Business Positioned for Organic Growth and New M&A Strategy
BUSINESS POSITIONED FOR ORGANIC GROWTH AND NEW M&A STRATEGY 1. Travelan®: • Sales expansion across target geographies • Growth in distribution network and sales & marketing initiatives • Product development (new formulations including once daily dosing) e.g. FDA approval 2. Protectyn®: • Sales expan
Slide 12: Contact Information
EMAIL: STEVE@IMMURON.COM PHONE: AUSTRALIA: +613 8892 4854 12 STEVEN LYDEAMORE CHIEF EXECUTIVE OFFICER IMMURON LIMITED CONTACT INFORMATION:
Slide 13: Scientific References
SCIENTIFIC REFERENCES Travelan® (IMM - 124E) Scandinavian Journal of Gastroenterology, 46:7 - 8, 862 - 868, DOI: 10.3109/00365521.2011.574726 Travelan® has been shown to reduce both the incidence and severity of ETEC - induced diarrhea in up to 90% of volunteers Immuron Limited, 29 April, 2011 Trave
Slide 14: ASX Releases Referenced
ASX RELEASES REFERENCED ASX Release Slide statement Ref Immuron Receives FDA Approval for Travelan IND Application Travelan® (IMM - 124E) IND filed with and approved by FDA a Immuron awarded A$6.2 million US DoD funding for Travelan US Department of Defense grant of US$4.45 million to examine a dosi